Anne O’Hagan

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

R. Huddart, M. Fleming, B. Mellado, 2019, The New England journal of medicine.

Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.

R. Huddart, B. Mellado, S. Park, 2023, European urology open science.

Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma

N. Goeyvaerts, J. P. Perez Ruixo, D. Ouellet, 2022, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

J. P. Perez Ruixo, D. Ouellet, I. Poggesi, 2021, CPT: pharmacometrics & systems pharmacology.

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.

Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites

P. Haney, V. Goodman, D. Ouellet, 2014, Journal of clinical pharmacology.

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

D. Schadendorf, P. Ascierto, A. Ribas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

T. Powles, T. Kang, A. Siefker-Radtke, 2023, Journal of Clinical Oncology.

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf, P. Ascierto, A. Ribas, 2014 .

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

A. Hauschild, D. Schadendorf, K. Flaherty, 2015, Clinical Cancer Research.